Literature DB >> 10173366

Managed care guidelines for the economic evaluation of pharmaceuticals.

P C Langley1, R E Martin.   

Abstract

Foundation Health Corporation, through its National Pharmacy and Therapeutics Committee, requires all pharmaceutical manufacturers and others who wish products to be considered for formulary listing to meet evidentiary and analytical standards in their submission documentation. This article details the evidentiary and analytical standards required from those making submissions and describes the methodological basis of the guidelines. This is the first time, as far as the authors are aware, that a managed care health system in the United States has required formulary submissions not only to meet clinical and economic evaluation standards, but also to take explicit account of the perspective of the managed care group in applying these techniques. Submissions are required to take what is described as a systems impact perspective. This approach is quite different, in both evidentiary and analytical terms, from standards required by health systems in other countries and standards for the economic evaluation of pharmaceuticals proposed by expert groups in the United States.

Mesh:

Year:  1997        PMID: 10173366

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  3 in total

Review 1.  Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

Authors:  R Baltussen; R Leidl; A Ament
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  Does managed care fuel pharmaceutical industry growth?

Authors:  M D Murray; F W Deardorff
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

3.  Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities.

Authors:  P C Langley
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.